Update on the treatment of lupus nephritis

Kidney International

Volumn 70, Issue 8, 2006, Pages 1403-1412

  Waldman, M ^a   Appel, G B ^b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Cytotoxic agents; Lupus nephritis; Membranous lupus; Mycophenolate mofetil; Rituximab

Indexed keywords

ABETIMUS; AZATHIOPRINE; B7 ANTIGEN; CD20 ANTIGEN; CD28 ANTIGEN; CD40 LIGAND; CD69 ANTIGEN; CD86 ANTIGEN; CHEMOKINE; CHLORAMBUCIL; COMPLEMENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; CYTOTOXIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOUBLE STRANDED DNA; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INDUCIBLE NITRIC OXIDE SYNTHASE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; RITUXIMAB; TOLL LIKE RECEPTOR;

ATHEROSCLEROSIS; BONE DISEASE; CANCER RISK; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFERTILITY; LUPUS ERYTHEMATOSUS NEPHRITIS; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RELAPSE; REMISSION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

CHEMOTHERAPY, ADJUVANT; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; RANDOMIZED CONTROLLED TRIALS;

EID: 33749531577     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5001777     Document Type: Review

References (149)

1. Fiehn C, Hajjar Y, Mueller K et al. Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment. Ann Rheum Dis 2003; 62: 435-439.
2. Bono L, Cameron JS, Hicks JA. The very long-term prognosis and complications of lupus nephritis and its treatment. QJM 1999; 92: 211-218.
3. Uramoto KM, Michet Jr CJ, Thumboo J et al. Trends in the incidence and mortality of systemic lupus erythematosus 1950-1992. Arthritis Rheum 1999; 42: 46-50.
4. Boumpas DT, Austin III HA, Vaughn EM et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340: 741-745.
5. Gourley MF, Austin III HA, Scott D et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis, A randomized, controlled trial. Ann Intern Med 1996; 125: 549-557.
6. Illei GG, Austin HA, Crane M et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135: 248-257.
7. Austin III HA, Klippel JH, Balow JE et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614-619.
8. Boumpas DT, Austin III HA, Vaughan EM et al. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993; 119: 366-369.
9. Mok CC, Lau CS, Wong RW. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum 1998; 41: 831-837.
10. Radis CD, Kahl LE, Baker GL et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year follow-up study. Arthritis Rheum 1995; 38: 1120-1127.
11. Korbet SM, Lewis EJ, Schwartz MM et al. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 2000; 35: 904-914.
12. Houssiau FA, Vasconcelos C, D'Cruz D et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46: 2121-2131.
13. Dooley MA, Hogan S, Jennette C et al. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int 1997; 51: 1188-1195.
14. Austin III HA, Boumpas DT, Vaughan EM et al. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int 1994; 45: 544-550.
15. Bakir AA, Levy PS, Dunea G. The prognosis of lupus nephritis in African-Americans: a retrospective analysis. Am J Kidney Dis 1994; 24: 159-171.
16. Austin III HA, Boumpas DT, Vaughan EM et al. High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant 1995; 10: 1620-1628.
17. Barr RG, Seliger S, Appel GB et al. Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity. Nephrol Dial Transplant 2003; 18: 2039-2046.
18. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85-118.
19. Eugui EM, Almquist SJ, Muller CD et al. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol 1991; 33: 161-173.
20. Hauser IA, Renders L, Radeke HH et al. Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion. Nephrol Dial Transplant 1999; 14: 58-63.
21. Badid C, Vincent M, McGregor B et al. Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney. Kidney Int 2000; 58: 51-61.
22. Blaheta RA, Leckel K, Wittig B et al. Mycophenolate mofetil impairs transendothelial migration of allogeneic CD4 and CD8 T-cells. Transplant Proc 1999; 31: 1250-1252.
23. Heemann U, Azuma H, Schmid C et al. Effects of mycophenolic acid mofetil on acute rejection of kidney allografts in rats. Clin Nephrol 1996; 45: 355-357.
24. Lui SL, Tsang R, Wong D et al. Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/lpr mice. Lupus 2002; 11: 411-418.
25. Corna D, Morigi M, Facchinetti D et al. Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. Kidney Int 1997; 51: 1583-1589.
26. Van Bruggen MC, Walgreen B, Rijke TP et al. Attenuation of murine lupus nephritis by mycophenolate mofetil. J Am Soc Nephrol 1998; 9: 1407-1415.
27. Buratti S, Szer IS, Spencer CH et al. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J Rheumatol 2001; 28: 2103-2108.
28. Karim MY, Alba P, Cuadrado MJ et al. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology (Oxford) 2002; 41: 876-882.
29. Kingdon EJ, McLean AG, Psimenou E et al. The safety and efficacy of MMF in lupus nephritis: a pilot study. Lupus 2001; 10: 606-611.
30. Chan TM, Li FK, Tang CS et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000; 343: 1156-1162.
31. Chan TM, Tse KC, Tang CS et al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16: 1076-1084.
32. Hu W, Liu Z, Chen H et al. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chin Med J (England) 2002; 115: 705-709.
33. Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-2228.
34. Ponticelli C, Moroni G. Flares in lupus nephritis: incidence, impact on renal survival and management. Lupus 1998; 7: 635-638.
35. El Hachmi M, Jadoul M, Lefebvre C et al. Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome. Lupus 2003; 12: 692-696.
36. Moroni G, Quaglini S, Maccario M et al. 'Nephritic flares' are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int 1996; 50: 2047-2053.
37. Contreras G, Pardo V, Leclercq B et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350: 971-980.
38. Jacobi AM, Diamond B. Balancing diversity and tolerance: lessons from patients with systemic lupus erythematosus. J Exp Med 2005; 202: 341-344.
39. Lipsky PE. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2001; 2: 764-766.
40. Waldman M, Madaio MP. Pathogenic autoantibodies in lupus nephritis. Lupus 2005; 14: 19-24.
41. Abetimus: Abetimus sodium LJP 394. BioDrugs 2003; 17: 212-215.
42. Jones DS, Barstad PA, Feild MJ et al. Immunospecific reduction of antioligonucleotide antibody-forming cells with a tetrakis-oligonucleotide conjugate (LJP 394), a therapeutic candidate for the treatment of lupus nephritis. J Med Chem 1995; 38: 2138-2144.
43. Alarcon-Segovia D, Tumlin JA, Furie RA et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2003; 48: 442-454.
44. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003; 22: 7359-7368.
45. Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-2581.
46. Braendstrup P, Bjerrum OW, Nielsen OJ et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol 2005; 78: 275-280.
47. Cesaro S, Bisogno G, Pusiol A. Rituximab and factors predictive of response in chronic immune thrombocytopenic purpura of children. J Pediatr 2005; 147: 715 (author reply 715-716).
48. Lalayanni C, Stavroyianni N, Saloum R et al. Rituximab is effective for selected patients with chronic steroid-refractory immune thrombocytopenic purpura. Hematology 2004; 9: 287-289.
49. Zaja F, Iacona I, Masolini P et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica 2002; 87: 189-195.
50. Tubman VN, Smoot L, Heeney MM. Acquired immune cytopenias post-cardiac transplantation respond to rituximab. Pediatr Blood Cancer 2006.
51. Ghijsels E, Lerut E, Vanrenterghem Y et al. Anti-CD20 monoclonal antibody (rituximab) treatment for hepatitis C-negative therapy-resistant essential mixed cryoglobulinemia with renal and cardiac failure. Am J Kidney Dis 2004; 43: e34-38.
52. Arzoo K, Sadeghi S, Liebman HA. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis 2002; 61: 922-924.
53. Garrett Jr HE, Groshart K, Duvall-Seaman D et al. Treatment of humoral rejection with rituximab. Ann Thorac Surg 2002; 74: 1240-1242.
54. Aranda Jr JM, Scornik JC, Normann SJ et al. Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report. Transplantation 2002; 73: 907-910.
55. Kay J, McCluskey RT. Case records of the Massachusetts General Hospital. Case 31-2005. A 60-year-old man with skin lesions and renal insufficiency. N Engl J Med 2005; 353: 1605-1613.
56. Jacobson SH, Vollenhoven RV, Gunnarsson I. Rituximab-induced long-term remission of membranous lupus nephritis. Nephrol Dial Transplant 2006; 21: 1742-1743.
57. Quartuccio L, Soardo G, Romano G et al. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia. efficacy and safety in the absence of steroids. Rheumatology (Oxford) 2006; 45: 784-785.
58. Basse G, Ribes D, Kamar N et al. Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients. Transplantation 2005; 80: 1560-1564.
59. Kallenbach M, Duan H, Ring T. Rituximab induced remission in a patient with Wegener's granulomatosis. Nephron Clin Pract 2005; 99: c92-c96.
60. Remuzzi G, Chiurchiu C, Abbate M et al. Rituximab for idiopathic membranous nephropathy. Lancet 2002; 360: 923-924.
61. Hainsworth JD. Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis. Arthritis Res Ther 2003; 5(Suppl 4): S12-S16.
62. Looney RJ, Anolik JH, Campbell D et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50: 2580-2589.
63. Leandro MJ, Edwards JC, Cambridge G et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002; 46: 2673-2677.
64. Leandro MJ, Cambridge G, Edwards JC et al. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 2005; 44: 1542-1545.
65. Perrotta S, Locatelli F, La Manna A et al. Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Br J Haematol 2002; 116: 465-467.
66. Ng KP, Leandro MJ, Edwards JC et al. Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Ann Rheum Dis 2006; 65: 942-945.
67. Weide R, Heymanns J, Pandorf A et al. Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy. Lupus 2003; 12: 779-782.
68. Ten Cate R, Smiers FJ, Bredius RG et al. Anti-CD20 monoclonal antibody (rituximab) for refractory autoimmune thrombocytopenia in a girl with systemic lupus erythematosus. Rheumatology (Oxford) 2004; 43: 244.
69. Sfikakis PP, Boletis JN, Lionaki S et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005; 52: 501-513.
70. Anolik JH, Barnard J, Cappione A et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004; 50: 3580-3590.
71. Tokunaga M, Fujii K, Saito K et al. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology (Oxford) 2005; 44: 176-182.
72. Chambers CA, Allison JP. Co-stimulation in T cell responses. Curr Opin Immunol 1997; 9: 396-404.
73. Greenfield EA, Nguyen KA, Kuchroo VK. CD28/B7 costimulation: a review. Crit Rev Immunol 1998; 18: 389-418.
74. Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001; 19: 225-252.
75. Biancone L, Deambrosis I, Camussi G. Lymphocyte costimulatory receptors in renal disease and transplantation. J Nephrol 2002; 15: 7-16.
76. Davidson A, Wang X, Mihara M et al. Co-stimulatory blockade in the treatment of murine systemic lupus erythematosus (SLE). Ann NY Acad Sci 2003; 987: 188-198.
77. Yellin MJ, Thienel U. T cells in the pathogenesis of systemic lupus erythematosus: potential roles of CD154-CD40 interactions and costimulatory molecules. Curr Rheumatol Rep 2000; 2: 24-31.
78. Katsiari CG, Liossis SN, Souliotis VL et al. Aberrant expression of the costimulatory molecule CD40 ligand on monocytes from patients with systemic lupus erythematosus. Clin Immunol 2002; 103: 54-62.
79. Devi BS, Van Noordin S, Krausz T et al. Peripheral blood lymphocytes in SLE - hyperexpression of CD154 on T and B lymphocytes and increased number of double negative T cells. J Autoimmun 1998; 11: 471-475.
80. Bijl M, Horst G, Limburg PC et al. Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus. Ann Rheum Dis 2001; 60: 523-526.
81. Koshy M, Berger D, Crow MK. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 1996; 98: 826-837.
82. Desai-Mehta A, Lu L, Ramsey-Goldman R et al. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996; 97: 2063-2073.
83. Howland KC, Ausubel LJ, London CA et al. The roles of CD28 and CD40 ligand in T cell activation and tolerance. J Immunol 2000; 164: 4465-4470.
84. Wang X, Huang W, Mihara M et al. Mechanism of action of combined short-term CTLA4Ig and anti-CD40 ligand in murine systemic lupus erythematosus. J Immunol 2002; 168: 2046-2053.
85. Grammer AC, Lipsky PE. CD154-CD40 interactions mediate differentiation to plasma cells in healthy individuals and persons with systemic lupus erythematosus. Arthritis Rheum 2002; 46: 1417-1429.
86. Katsiari CG, Liossis SN, Dimopoulos AM et al. CD40L overexpression on T cells and monocytes from patients with systemic lupus erythematosus is resistant to calcineurin inhibition. Lupus 2002; 11: 370-378.
87. Cron RQ, Bandyopadhyay R, Genin A et al. Early growth response-1 is required for CD154 transcription. J Immunol 2006; 176: 811-818.
88. Liang B, Gee RJ, Kashgarian MJ et al. B7 costimulation in the development of lupus: autoimmunity arises either in the absence of B7.1/B7.2 or in the presence of anti-b7.1/B7.2 blocking antibodies. J Immunol 1999; 163: 2322-2329.
89. Folzenlogen D, Hofer MF, Leung DY et al. Analysis of CD80 and CD86 expression on peripheral blood B lymphocytes reveals increased expression of CD86 in lupus patients. Clin Immunol Immunopathol 1997; 83: 199-204.
90. Wong CK, Lit LC, Tam LS et al. Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005; 44: 989-994.
91. Quezada SA, Eckert M, Adeyi OA et al. Distinct mechanisms of action of anti-CD154 in early versus late treatment of murine lupus nephritis. Arthritis Rheum 2003; 48: 2541-2554.
92. Boumpas DT, Furie R, Manzi S et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003; 48: 719-727.
93. Kalunian KC, Davis Jr JC, Merrill JT et al. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 3251-3258.
94. Davis Jr JC, Totoritis MC, Rosenberg J et al. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol 2001; 28: 95-101.
95. Jenkins MK, Taylor PS, Norton SD et al. CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J Immunol 1991; 147: 2461-2466.
96. Riley JL, Blair PJ, Musser JT et al. ICOS costimulation requires IL-2 and can be prevented by CTLA-4 engagement. J Immunol 2001; 166: 4943-4948.
97. Schwartz RH. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992; 71: 1065-1068.
98. Takahashi T, Tagami T, Yamazaki S et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000; 192: 303-310.
99. Birebent B, Lorho R, Lechartier H et al. Suppressive properties of human CD4+CD25+ regulatory T cells are dependent on CTLA-4 expression. Eur J Immunol 2004; 34: 3485-3496.
100. Walunas TL, Bakker CY, Bluestone JA. CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 1996; 183: 2541-2550.
101. Linsley PS, Brady W, Urnes M et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991; 174: 561-569.
102. Collins AV, Brodie DW, Gilbert RJ et al. The interaction properties of costimulatory molecules revisited. Immunity 2002; 17: 201-210.
103. Linsley PS, Greene JL, Brady W et al. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1994; 1: 793-801.
104. Brunner MC, Chambers CA, Chan FK et al. CTLA-4-Mediated inhibition of early events of T cell proliferation. J Immunol 1999; 162: 5813-5820.
105. Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 1996; 183: 2533-2540.
106. Greenwald RJ, Boussiotis VA, Lorsbach RB et al. CTLA-4 regulates induction of anergy in vivo. Immunity 2001; 14: 145-155.
107. Tivol EA, Gorski J. Re-establishing peripheral tolerance in the absence of CTLA-4: complementation by wild-type T cells points to an indirect role for CTLA-4. J Immunol 2002; 169: 1852-1858.
108. Darlington PJ, Kirchhof MG, Criado G et al. Hierarchical regulation of CTLA-4 dimer-based lattice formation and its biological relevance for T cell inactivation. J Immunol 2005; 175: 996-1004.
109. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994; 265: 1225-1227.
110. Larsen CP, Pearson TC, Adams AB et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005; 5: 443-453.
111. Kremer JM, Westhovens R, Leon M et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003; 349: 1907-1915.
112. Kremer JM, Dougados M, Emery P et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52: 2263-2271.
113. Genovese MC, Becker JC, Schiff M et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005; 353: 1114-1123.
114. Moreland LW, Alten R, Van den Bosch F et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002; 46: 1470-1479.
115. Vincenti F, Larsen C, Durrbach A et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770-781.
116. Daikh DI, Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol 2001; 166: 2913-2916.
117. Llorente L, Richaud-Patin Y, Garcia-Padilla C et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 2000; 43: 1790-1800.
118. Stohl W, Metyas S, Tan SM et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003; 48: 3475-3486.
119. Stohl W. Targeting B lymphocyte stimulator in systemic lupus erythematosus and other autoimmune rheumatic disorders. Expert Opin Ther Targets 2004; 8: 177-189.
120. Zhang J, Roschke V, Baker KP et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001; 166: 6-10.
121. Crow MK. Interferon-alpha: a new target for therapy in systemic lupus erythematosus? Arthritis Rheum 2003; 48: 2396-2401.
122. Baechler EC, Gregersen PK, Behrens TW. The emerging role of interferon in human systemic lupus erythematosus. Curr Opin Immunol 2004; 16: 801-807.
123. Schwarting A, Paul K, Tschirner S et al. Interferon-beta: a therapeutic for autoimmune lupus in MRL-Faslpr mice. J Am Soc Nephrol 2005; 16: 3264-3272.
124. Leadbetter EA, Rifkin IR, Hohlbaum AM et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002; 416: 603-607.
125. Anders HJ, Vielhauer V, Eis V et al. Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice. Faseb J 2004; 18: 534-536.
126. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002; 20: 709-760.
127. Patole PS, Zecher D, Pawar RD et al. G-rich DNA suppresses systemic lupus. J Am Soc Nephrol 2005; 16: 3273-3280.
128. Li Y, Zheng XX, Li XC et al. Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment. Transplantation 1998; 66: 1387-1388.
129. Li Y, Li XC, Zheng XX et al. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999; 5: 1298-1302.
130. Sloan RP, Schwartz MM, Korbet SM et al. Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. Lupus Nephritis Collaborative Study Group. J Am Soc Nephrol 1996; 7: 299-305.
131. Pasquali S, Banfi G, Zucchelli A et al. Lupus membranous nephropathy: long-term outcome. Clin Nephrol 1993; 39: 175-182.
132. Donadio Jr JV, Burgess JH, Holley KE. Membranous lupus nephropathy: a clinicopathologic study. Medicine (Baltimore) 1977; 56: 527-536.
133. Adler SG, Johnson K, Louie JS et al. Lupus membranous glomerulonephritis: different prognostic subgroups obscured by imprecise histologic classifications. Mod Pathol 1990; 3: 186-191.
134. Weening JJ, D'Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004; 65: 521-530.
135. Weening JJ, D'Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15: 241-250.
136. Donadio Jr JV. Treatment of lupus nephritis. Nephron 1977; 19: 186-189.
137. Radhakrishnan J, Kunis CL, D'Agati V et al. Cyclosporine treatment of lupus membranous nephropathy. Clin Nephrol 1994; 42: 147-154.
138. Hallegua D, Wallace DJ, Metzger AL et al. Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature. Lupus 2000; 9: 241-251.
139. Karim MY, Pisoni CN, Ferro L et al. Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy. Rheumatology (Oxford) 2005; 44: 1317-1321.
140. Chan TM, Li FK, Hao WK et al. Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression. Lupus 1999; 8: 545-551.
141. Moroni G, Maccario M, Banfi G et al. Treatment of membranous lupus nephritis. Am J Kidney Dis 1998; 31: 681-686.
142. Hu W, Liu Z, Shen S et al. Cyclosporine A in treatment of membranous lupus nephropathy. Chin Med J (England) 2003; 116: 1827-1830.
143. Mok CC, Ying KY, Lau CS et al. Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: an open-label trial. Am J Kidney Dis 2004; 43: 269-276.
144. Kapitsinou PP, Boletis JN, Skopouli FN et al. Lupus nephritis: treatment with mycophenolate mofetil. Rheumatology (Oxford) 2004; 43: 377-380.
145. Spetie DN, Tang Y, Rovin BH et al. Mycophenolate therapy of SLE membranous nephropathy. Kidney Int 2004; 66: 2411-2415.
146. Kanda H, Kubo K, Tateishi S et al. Antiproteinuric effect of ARB in lupus nephritis patients with persistent proteinuria despite immunosuppressive therapy. Lupus 2005; 14: 288-292.
147. Roman MJ, Shanker BA, Davis A et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399-2406.
148. Bruce IN, Urowitz MB, Gladman DD et al. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum 2003; 48: 3159-3167.
149. Nikpour M, Urowitz MB, Gladman DD. Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin N Am 2005; 31: 329-354 (vii-viii).